In December 2025, BioMarin entered into a definitive agreement to acquire all outstanding shares of Amicus for $14.50 per share in cash, totaling $4.8 billion. The deal is expected to be closed in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results